Interferon beta-1b biosimilar (Pfenex)

干扰素β-1b生物类似药(Pfenex)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameInterferon beta-1b biosimilar (Pfenex)
Drug Alias Name干扰素β-1b生物仿制药(Pfenex)PF-530
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfenex Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfenex Inc
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeL03AB08
Related LinksN/A